BASEL (dpa-AFX) - Novartis (NVS) announced updated results from Phase II
study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive
(ALK+) non-small cell lung cancer (NSCLC) patients taking Zykadia (ceritinib).
BASEL (dpa-AFX) - Novartis (NVS) announced data from the Phase III COMBI-v
study showing an overall survival and a progression-free survival benefit for
patients with BRAF V600 mutation-positive advanced melanoma when treated
first-line with the...
Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior
progression-free survival as first-line treatment for HR+/HER2- advanced breast
cancer compared to a standard of care
Novartis International AG /